Zicronapine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Zicronapine
Zicronapine.svg
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27ClN2
Molar mass354.9 g/mol g·mol−1
3D model (JSmol)

Zicronapine (/zˈkrɒnəpn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.[1]

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.[2]

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic Lu AF35700 (a prodrug of Lu AF356152).[3]

References[edit]

  1. ^ "The clinical phase III programme commenced on zicronapine". January 20, 2011. Retrieved 6 February 2014.
  2. ^ "Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work". December 18, 2009. Retrieved 6 February 2014.
  3. ^ "Performance in 2014 positions Lundbeck well for 2015 and beyond" (PDF). February 5, 2015. Retrieved 18 June 2015.